Abstract
Aim Colorectal cancer (CRC) is one of the most common cancers in the world. However, the role of immune checkpoint molecules, especially Programmed cell death protein 1 (PD-1) and Programmed cell death-ligand 1 (PD-L1), in the progression of CRC remains unclear. This systematic review and meta-analysis will investigate the prognostic significance of PD-1/PD-L1 expression on tumor-infiltrating immune cells and tumor cells in patients with colorectal cancer.
Methods This protocol has been prospectively registered in the PROSPERO (registration NO. CRD42020156233). A comprehensive electronic search on PubMed/MEDLINE, Scopus, Web of Science (WOS), Embase and ProQuest will be conducted using a combination of MeSH terms of “programmed cell death 1”, “programmed cell death ligand 1”, “colorectal” and “cancer” between 1 January 1990 and 31 March 2021 with no language limitation. Two independent reviewers will perform study selection, data extraction, and risk of bias assessment. The Newcastle-Ottawa Scale (NOS) for cohort studies will be used to assess the risk of bias. In the case of sufficient data, either random or fixed-effect models, will be used for meta-analysis. Statistical heterogeneity will be evaluated by 𝒳2 test with the I2 statistic. “Funnel plot”, “Begg’s statistical test”, and “Egger’s statistical test and graph” will be used to assess publication bias. Stata V.13 software will be employed for meta-analysis.
Results and conclusion According to the meta-analysis of the aggregated data from the relevant primary studies, the relationship between expression of PD-1/PD-L1 and prognostic parameters, including progression-free survival and overall survival, will be reported. The results of the current study will be published in a peer-reviewed journal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Iran University of Medical Sciences under Grant (99-1-4-17381).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Ethics committee of the Iran University of Medical Sciences (NO. IR.IUMS.REC.1399.559)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail address of authors: Fateme.abediny{at}gmail.com, salehi_saeedeh{at}yahoo.com, leila.janani{at}gmail.com, monirehmohsenzadegan{at}gmail.com
Data Availability
The data that support this study are available on request from the corresponding author. The data are not publicly available due to the ongoing process of this study.
